STK-001 lowers seizures, aids cognition and behavior, trials finding
Treatment with STK-001 led to a marked reduction in seizure frequency, and aided cognition and behavior, among children and adolescents with Dravet syndrome in early clinical trials, according to new findings announced by the therapy’s developer Stoke Therapeutics. “Together these data support the potential for STK-001 to…